ATE396718T1 - Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion - Google Patents

Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion

Info

Publication number
ATE396718T1
ATE396718T1 AT04814853T AT04814853T ATE396718T1 AT E396718 T1 ATE396718 T1 AT E396718T1 AT 04814853 T AT04814853 T AT 04814853T AT 04814853 T AT04814853 T AT 04814853T AT E396718 T1 ATE396718 T1 AT E396718T1
Authority
AT
Austria
Prior art keywords
compound
methods
compositions
hcv
infection
Prior art date
Application number
AT04814853T
Other languages
English (en)
Inventor
Elzbieta Holsztynska
Ray Lo
Thomas Sun
Steven Wang
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE396718T1 publication Critical patent/ATE396718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04814853T 2003-12-19 2004-12-18 Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion ATE396718T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53154303P 2003-12-19 2003-12-19

Publications (1)

Publication Number Publication Date
ATE396718T1 true ATE396718T1 (de) 2008-06-15

Family

ID=34738664

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04814853T ATE396718T1 (de) 2003-12-19 2004-12-18 Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion

Country Status (7)

Country Link
US (1) US20050249805A1 (de)
EP (1) EP1699446B1 (de)
JP (1) JP2007514763A (de)
AT (1) ATE396718T1 (de)
DE (1) DE602004014189D1 (de)
ES (1) ES2308302T3 (de)
WO (1) WO2005063225A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7971730B2 (en) 2005-08-10 2011-07-05 The Regents Of The University Of California Collection tubes apparatus, systems and methods
EP2171096A4 (de) * 2007-06-08 2011-02-23 Musc Found For Res Dev Carboxylesterase-1-polymorphismen und verfahren zu ihrer verwendung
WO2009009115A2 (en) * 2007-07-11 2009-01-15 Nevsky Pharmaceutical Development Liposome compositions for treatment of hepatitis c
US8182826B2 (en) * 2007-09-11 2012-05-22 Whitmire A Jeffrey Refreshment towel and applied solution
US10966431B2 (en) * 2007-09-11 2021-04-06 Freedom Towel Holdings, LLC. Refreshment towel and applied solution
US9669405B2 (en) 2012-10-22 2017-06-06 The Regents Of The University Of California Sterilizable photopolymer serum separator
US9730867B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Methods of forming a slurry with microcapsules formed from phosphate esters
US9732303B2 (en) 2016-01-06 2017-08-15 The Procter & Gamble Company Microcapsules formed from phosphate esters and compositions containing same
US10154947B2 (en) 2016-01-06 2018-12-18 The Procter & Gamble Company Antiperspirant composition
CN110220757B (zh) * 2019-06-05 2021-08-24 浙江龙传生物医药科技有限公司 用于药物代谢检测的血液保存剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971618A (en) * 1971-04-16 1990-11-20 Ici Americas Inc. Herbicide compositions
ATE440096T1 (de) * 2000-12-08 2009-09-15 Takeda Pharmaceutical Substituierte thiazolderivate mit 3- pyridylgruppen, verfahren zu deren herstellung und deren verwendung
EP1530569A2 (de) * 2002-08-23 2005-05-18 Rigel Pharmaceuticals, Inc. Pyridylsubstituierte heterocyclen zur behandlung oder verhinderung von hcv infektion

Also Published As

Publication number Publication date
EP1699446B1 (de) 2008-05-28
JP2007514763A (ja) 2007-06-07
DE602004014189D1 (de) 2008-07-10
ES2308302T3 (es) 2008-12-01
WO2005063225A8 (en) 2005-08-25
EP1699446A1 (de) 2006-09-13
US20050249805A1 (en) 2005-11-10
WO2005063225A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
BRPI0415373A (pt) ácidos carboxìlicos macrocìclicos e acilsulfonamidas como inibidores de replicação de hcv
DK2250163T3 (da) Hepatitis C-virusinhibitorer
CY1109216T1 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
TW200612898A (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
IS7533A (is) Lifrarbólgu C-veirutálmar
EA200900297A1 (ru) Ингибиторы вируса гепатита с
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
TW200510391A (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2005007681A3 (en) Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
UA91677C2 (ru) Макроциклические соединения как ингибиторы вирусной репликации
ATE250080T1 (de) Hcv ns3 proteaseinhibitoren
ATE396718T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
MY141506A (en) Virus therapeutic drug
TNSN06103A1 (en) Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
NZ600527A (en) Antiviral compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1699446

Country of ref document: EP

REN Ceased due to non-payment of the annual fee